Agents were informed that they would no longer receive commissions for select signs up as of November 1.
The National Association of Benefits and Insurance Professionals (NABIP) issued a statement in response to Aetna and Elevance Health (Anthem) announcing that as of November 1, they would no longer pay commissions for new enrollment for select Medicare plans.1
In a press release, NABIP CEO Jessica Brooks-Woods said, “By eliminating agent commissions in certain Medicare plans, Aetna and Anthem have created a substantial barrier for seniors who rely on agents to understand their plan options, manage costs, and access the care they need. This disruption hits particularly hard at a time when seniors are already grappling with higher prescription costs and shrinking benefits in their Medicare Advantage plans.”
She continued, “Our Medicare agents are essential advocates who help beneficiaries make informed coverage decisions, assist with navigating plan changes, and resolve complex claim issues, providing stability and support that is now at risk. Without assistance from Medicare agents, beneficiaries could face significant challenges that could compromise their access to personalized guidance and cost-effective choices.”
According to the NABIP, some agents and brokers were only notified of the change with less than 24 hours notices.
Brooks-Woods continued, “We call on Aetna, Anthem, and other industry leaders to collaborate with NABIP to find a sustainable solution that maintains the critical support our seniors need. Together, we can protect access to knowledgeable Medicare guidance, ensuring our healthcare system remains accessible, reliable, and dignified for all. NABIP reiterates its commitment to supporting agents, brokers, and the communities they serve through our Healthcare Bill of Rights. Our mission is to ensure that every American has access to quality, affordable healthcare guided by professionals who prioritize patient advocacy and equitable healthcare solutions."
The NABIP first announced its Healthcare Bill of Rights in March of this year.2 The goal of the initiative was to provide guidelines that would improve healthcare delivery systems for all Americans.
In a press release issued at the time, Brooks-Woods said, “NABIP's Healthcare Bill of Rights articulates the core values and principles of the association. They represent not just our beliefs but NABIP's commitment to ensuring that every American is empowered with the right to high-quality, affordable healthcare. These rights stand as the pillars by which we define our mission, measure our progress, and drive toward a future where equitable healthcare is not a privilege but a standard for all."
She continued, “The announcement of NABIP's Healthcare Bill of Rights took place at our recent Capitol Conference, showcasing NABIP's dedication to shaping a healthcare system that prioritizes the well-being and rights of all Americans. This significant milestone is a cornerstone in our commitment to creating a healthcare landscape that is privately accessible and affordable for every citizen."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.